The Medicine Maker: A New Focus for Cancer Therapeutics

News
Published: 17 December 2021 Author: Joe Sinclair, Vice President, Business Development & Corporate Strategy

The Medicine Maker recently featured Joe Sinclair, Vice President, Business Development & Corporate Strategy at Vibalogics exploring the topic of oncolytic virotherapy and aspects of variable target virus selection, clinical patient access, manufacturability and more.

To read The Medicine Maker article: https://themedicinemaker.com/manufacture/a-new-focus-for-cancer-therapeutics

We’re the ideal CDMO for your Virotherapy project

Get in touch

SERVICE OFFERING

Looking for something different?

Vibalogics can assist you through a comprehensive service portfolio – ensuring success of your virotherapy, beginning with process development and technical transfer feasibility, through cGMP production and validation.

Related

What to read next

Lab Manager: Virotherapy GMP Site Expands …

Stefan Beyer, PhD, President and Managing Director recently sat down with Lab Manager to discuss ongoi…

Vibalogics Establishes Scientific Advisory…

Vibalogics, a global contract development and manufacturing organization (CDMO) and recognized leader …

BioProcess International: CDMOs are now th…

Roger Lias, PhD, Chief Commercial Officer recently sat down with BioProcess International to discuss h…